Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care expenditures based on current market shares of Bup/Nal film and generic Bup/Nal tablet. (Source: Drug and Alcohol Dependence)

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit opioid use and treatment completion among POD patients treated in primary care. (Source: Drug and Alcohol Dependence)

This study extends the comparison of diversion and abuse rates between buprenorphine sublingual formulations. (Source: Drug and Alcohol Dependence)

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care expenditures based on current market shares of Bup/Nal film and generic Bup/Nal tablet. (Source: Drug and Alcohol Dependence)

Aims: The approval of extended release injectable naltrexone suspension (XR-NTX) has introduced a new option for treating opioid addiction, but the absence of physiological opioid dependence is a necessary and challenging first step for starting therapy. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of opioids to resolve. We summarize findings from an open label study that tested whether the transition from opioid addiction to XR-NTX can be safely and effectively performed in an office-based setting using very low dose oral naltrexone and buprenorphine/naloxone (NTX/BUP). (Source: Drug and Alcohol Dependence)

Aims: The approval of extended release injectable naltrexone suspension (XR-NTX) has introduced a new option for treating opioid addiction, but the absence of physiological opioid dependence is a necessary and challenging first step for starting therapy. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of opioids to resolve. We summarize findings from an open label study that tested whether the transition from opioid addiction to XR-NTX can be safely and effectively performed in an office-based setting using very low dose oral naltrexone and buprenorphine/naloxone (NTX/BUP). (Source: Drug and Alcohol Dependence)

Aims: The 10-site Prescription Opioid Addiction Treatment Study, conducted in the NIDA Clinical Trials Network, examined different lengths of buprenorphine-naloxone (bup-nx) plus medical management, with or without additional counseling, for patients dependent upon prescription opioids. Among patients (N=360) receiving 12 weeks of bup-nx stabilization, 49% achieved successful opioid use outcomes at week 12. The aim of this secondary analysis is to examine the ability to predict outcome (and thus potentially alter the treatment) based on early (weeks 1–4) treatment response. (Source: Drug and Alcohol Dependence)

Aims: Buprenorphine ingestion can cause life-threatening poisoning in young children. Previous reports have found that film formulations are associated with lower pediatric exposure rates than tablet formulations. The purpose of this study is to determine whether these relationships are stable over time. (Source: Drug and Alcohol Dependence)